Key result
A 0.1 mm increase in mean in-stent late loss with drug-eluting stents was associated with a 1.8 increase in the number needed to treat to prevent one target lesion revascularization.
Why the study?
Does the degree of in-stent late loss (ISLL) after drug-eluting stent implantation predict the clinical benefit (NNT to prevent TLR) compared to bare-metal stents?
Meta-Analysis (n=8,641)
Does the degree of in-stent late loss (ISLL) after drug-eluting stent implantation predict the clinical benefit (NNT to prevent TLR) compared to bare-metal stents?
There is a strong association between the angiographic efficacy of DES (inhibition of neointimal hyperplasia) and its clinical benefit in preventing target lesion revascularization.
Answers are grounded in this paper and cite their sources.
Validates in-stent late loss as a surrogate for DES clinical benefit versus bare-metal stents; confirms the angiographic-clinical efficacy link in stent trials.
AIMS: Controversy exists about the clinical significance of in-stent late loss (ISLL) after drug-eluting stent (DES) implantation. We sought to clarify whether ISLL after DES implantation is related to a potential clinical impact. METHODS AND RESULTS: We included in a meta-regression analysis 21 trials (8641 patients) that randomly compared DES with bare-metal stents (BMS). We evaluated the relationship between angiographic behaviour of DES and the clinical impact of using DES instead of BMS in each trial using meta-regression techniques, weighting by the number of patients included in each trial. Mean ISLL in patients allocated to DES and DeltaISLL (difference in ISLL in patients allocated to BMS and DES) were used as angiographic parameters of efficacy of DES. The number of patients needed to be treated (NNT) to prevent one target lesion revascularization (TLR) was used to quantify the clinical impact of using DES instead of BMS. There was a significant relationship between mean ISLL in patients allocated to DES and the clinical benefit of using DES instead of BMS, as measured with the NNT for TLR: NNT for TLR = 6.2 + 18.4 [ISLL-DES] (R = 0.62; P = 0.007). Therefore, a 0.1 mm increase in mean ISLL-DES was associated with a 1.8 increase in NNT for TLR. There was also a significant association between the degree of inhibition of neointimal hyperplasia of DES in comparison with BMS with the NNT for TLR: NNT for TLR = 17.1-11.8 [DeltaISLL] (R = 0.61; P = 0.008). Therefore, a 0.1 mm reduction in ISLL by using DES instead of BMS was associated with a 1.2 decrease in mean NNT for TLR. CONCLUSION: There is a strong and significant association between the degree of inhibition of neointimal formation with the use of DES and the clinical impact of using DES instead of BMS.
No takes yet. Share an insight, caveat, or question.
Moreno et al. (2007) conducted a meta-analysis in Coronary artery disease requiring stent implantation (n=8,641). Drug-eluting stents (DES) vs. Bare-metal stents (BMS) was evaluated on Number needed to treat (NNT) to prevent one target lesion revascularization (TLR) (R = 0.62, p=0.007). A 0.1 mm increase in mean in-stent late loss with drug-eluting stents was associated with a 1.8 increase in the number needed to treat to prevent one target lesion revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: